Acorda, Elan drug improves walking for MS patients
Acorda Therapeutics Inc. (ACOR.O: Quote, Profile, Research) said on Monday it will seek U.S. marketing approval early next year for the first medicine to improve walking among patients with multiple sclerosis, following highly favorable results of a second late-stage study.
Walk, wooble or roll here.
Biogen Idec Lobbying Efforts
I pay about $1,800 a month for Avonex. Here's one way Biogen spent $1.2 million, paying lobbying firms.
Pharmaceuticals spent $226,999,560 on lobbying last year.
All I can say is F*CK Them!
Biogen Idec to cut 17 percent of work force, sell assets
Drug maker Biogen Idec Inc. on Thursday said it will lay off 650 workers, or about 17 percent of its work force, as part of a plan to reduce annual expenses by $200 million to $300 million.
Elan Faces SEC Inquiry Into Trading
Elan Corp. (ELN.I: Quote, Profile, Research) (ELN.N: Quote, Profile, Research) on Monday said the U.S. Securities and Exchange Commission is probing securities trading around the Feb. 28 announcement of the suspension of sales of the multiple sclerosis drug Tysabri.
Elan shares dive on drug setback
Shares in Irish drugmaker Elan have plummeted once more after a third case of disease linked to Tysabri, its multiple sclerosis treatment.
Elan suspended the drug after two patients were found to have caught the rare disease, one of whom later died.
The newly revealed case - which also ended with the death of the patient - could mean Tysabri never makes it back onto the market, analysts warned.
By the close of trading, Elan shares were down 56% to 2.43 euros.
Biogen, Elan Voluntarily Withdraw MS Drug
More info here.
Biogen, Elan Suspend Tysabri After Death
Biogen Idec and Elan Corporation Plc on Monday suspended sales of their much-heralded new multiple sclerosis drug Tysabri after a patient died from a rare but frequently fatal central nervous system disease.
Biogen Idec Retools After FDA Clears Drug but Not Its Moniker
It seemed as if the Food and Drug Administration liked everything about Biogen Idec's new drug for multiple sclerosis.
Early this year, the FDA encouraged Biogen Idec and its partner, Elan Pharmaceuticals, to submit an application for approval a year ahead of schedule. The companies sought clearance based on one year of data from a pair of pivotal clinical trials, instead of two years, as originally planned. The agency said it would give the experimental drug priority review, cutting four months off the wait for an answer.
The agency's Nov. 23 ruling gave the companies the go-ahead to sell the drug as a stand-alone therapy or in combination with Avonex, Biogen Idec's big-selling MS drug.
Wall Street analysts called the dual approval a home run.
But there was one thing the regulators didn't like about the new drug: the name.
Amazon Indians battle in Ecuador over logging
Me travelling with the Huaorani
Penti Baihua, a community leader of the Huaorani Indians, knew there was more to the massacre of 26 members of a rival Amazon tribe than mere revenge.
In May 2003, nine Huaorani warriors from the village of Tiguino killed 26 Tagaeri men, women and children. They justified the massacre of nearly one- fifth of a tiny tribe that shuns outsiders as payback for a 1993 murder. But Colombian loggers may have instigated the raid so they could seek lucrative stands of Spanish cedar and a mahogany called aguano abundantly found on Tagaeri land, according to recent interviews with government officials, police investigators and several Huaorani leaders.
"They (the loggers) were scared of the Tagaeri and went to Tiguino," said Penti Baihua, a Huaorani leader who spoke with several of the nine raiders after the attack. "They told them: 'We'll give you gasoline and bullets if you kill the Tagaeri. We want to work in that area.' "
Irish drugmaker Elan narrows quarter loss
Irish pharmaceutical company Elan Corp.'s first-quarter loss narrowed amid reduced operating expenses.
The company also said it is on track to seek approval for its highly anticipated multiple sclerosis drug, Antegren....
Elan is developing Antegren with Biogen Idec Inc., of Cambridge, Mass. In February, the two companies said they planned to file for approval of Antegren a year ahead of schedule. Biogen Idec already sells the MS drug Avonex.